Language:

Can a medical need clause help manage the growing costs of prescription drugs in the EU?

Health economics, policy and law, 2016-04, Vol.11 (2), p.179-192 [Peer Reviewed Journal]

Cambridge University Press 2015 ;ISSN: 1744-1331 ;EISSN: 1744-134X ;DOI: 10.1017/S1744133115000389 ;PMID: 26333920

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Can a medical need clause help manage the growing costs of prescription drugs in the EU?
Author: Brooks, Eleanor ; Geyer, Robert
Subjects: Cost control ; Disease Management ; Drug Costs - legislation & jurisprudence ; Drug Discovery - legislation & jurisprudence ; Drug Industry - economics ; Drug Industry - legislation & jurisprudence ; Economic theory ; Europe ; European Union ; Expenditures ; Health care expenditures ; Health care policy ; Health economics ; Health Services Needs and Demand ; Innovations ; Patients ; Pharmaceutical industry ; Prescription drugs ; Prescription Drugs - economics ; Prescription Drugs - supply & distribution ; Prices ; R Prescription drugs ; R&D ; Regulation ; Research & development ; Studies
Is Part Of: Health economics, policy and law, 2016-04, Vol.11 (2), p.179-192
Description: Innovation in the development of new drugs has to balance the needs of health actors and administrators, the pharmaceutical industry and patients. Differing perspectives on what constitutes an innovation, where research and development should be directed and how new drugs should be evaluated and priced cause ongoing tensions within the regulatory framework. In the current climate, where Europe’s health systems face rising demand for health services and increasingly restricted resources, the efficiency of pharmaceutical regulation and drug development is under even greater scrutiny. How can regulation foster innovation and industry growth while also serving the public health needs of society, and what is the EU’s role in pursuing this objective? Drawing on a provision which formerly existed in Norwegian pharmaceutical legislation, this article explores the potential of a medical need clause (MNC) in addressing these issues. In restricting market authorisations to those drugs that offer an added therapeutic value, might a MNC foster innovation and spending efficiency in Europe’s health systems?
Publisher: Cambridge, UK: Cambridge University Press
Language: English
Identifier: ISSN: 1744-1331
EISSN: 1744-134X
DOI: 10.1017/S1744133115000389
PMID: 26333920
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Can a medical need clause help manage the growing costs of prescription drugs in the EU?

Cambridge University Press 2015 ;ISSN: 1744-1331 ;EISSN: 1744-134X ;DOI: 10.1017/S1744133115000389 ;PMID: 26333920

Searching Remote Databases, Please Wait